Aurinia Pharmaceuticals
Aurinia Pharmaceuticals' revenue rose 20.4% to $283 million in fiscal 2025. Its operating margin was 37.1%, up from −2.0% a year earlier. Free cash flow was $135 million, up 207.0%. It paid out $98 million in dividends and buybacks, 72% of free cash flow. The diluted share count fell 5.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Aurinia Pharmaceuticals does
Aurinia sells LUPKYNIS (voclosporin), a pill for adults with active lupus nephritis, a serious kidney disease caused by lupus. The company says it was the first FDA-approved oral therapy for this condition, in January 2021. It is also developing aritinercept for other autoimmune diseases.
In the United States Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor. For Europe and Japan it sells inventory to its partner Otsuka under a licensing deal, which also pays milestones and royalties. In 2025 its net product sales were $271.3 million. Lonza makes voclosporin for it under contract.
Aurinia is therefore closely tied to one product. It also repurchased some of its own shares in 2025.
Its biggest risks, as it describes them
- Depending heavily on the commercial success of LUPKYNIS, its one product.
- Its sales in Europe and Japan depend on its partner Otsuka meeting its contract duties.
- Pricing rules and insurance coverage may limit what it earns from LUPKYNIS.
- Patents covering LUPKYNIS may not hold up, and other companies may claim it infringes theirs.
- Drug development is long and uncertain, and early aritinercept results may not carry over.
Income statement
From fiscal 2024 to 2025, earnings per share grew 5,075.0% a year and net income 4,851.7% a year, as buybacks cut the share count by 5%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 232 | 94 | 49 | 83 | 80 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | −33.0x | −1.0x | 24.2x |
| Current ratio | 12.6x | 9.6x | 5.5x | 4.6x | 5.2x |
| Quick ratio | 12.2x | 9.1x | 5.0x | 4.2x | 4.8x |
Cash flow
Projections
Project Aurinia Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $25.1 million of Aurinia Pharmaceuticals shares on the open market, and 1 insider sold $546,373.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Stephen P. RobertsonChief Legal Officer | Sold | 11,939 | $15.95 | $190,427 | Form 4 |
| Aug 21, 2026 | Stephen P. RobertsonChief Legal Officer | Sold | 20,975 | $16.97 | $355,946 | Form 4 |
| Jun 2, 2026 | Kevin TangChief Executive Officer, Director, 10% owner | Bought | 206,005 | $15.28 | $3.1 million | Form 4 |
| Jun 1, 2026 | Kevin TangChief Executive Officer, Director, 10% owner | Bought | 343,620 | $15.28 | $5.3 million | Form 4 |
| May 29, 2026 | Kevin TangChief Executive Officer, Director, 10% owner | Bought | 264,981 | $15.31 | $4.1 million | Form 4 |
| Mar 3, 2026 | Kevin TangDirector | Bought | 184,208 | $14.22 | $2.6 million | Form 4 |
| Mar 2, 2026 | Kevin TangDirector | Bought | 199,353 | $14.26 | $2.8 million | Form 4 |
| Feb 27, 2026 | Kevin TangDirector | Bought | 516,439 | $13.99 | $7.2 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 11.5% | 52.7% | 68.2% |
| Altman Z'' | −0.24 | 0.84 | 5.18 |
| Accruals ratio | −8.8% | −7.0% | 23.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Aurinia Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals | FY25 | 20.4% | 37.1% | 47.8% | — | — | — | |
| Xeris Biopharma | FY25 | 43.7% | 8.5% | — | 19.6% | 4.2x | 7 | Compare |
| Rigel Pharmaceuticals | FY25 | 64.2% | 42.6% | — | 91.3% | −0.8x | 7 | Compare |
| Harrow | FY25 | 36.4% | 11.2% | 15.8% | — | 5.5x | 6 | Compare |
| Ironwood Pharmaceuticals | FY25 | −15.7% | 33.3% | 42.9% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 50 | 46 | 134 | 176 | 235 | 283 |
| Revenue growth | — | 141.6% | 10.8% | −31.3% | 15,660.4% | −9.0% | 193.9% | 30.9% | 34.0% | 20.4% |
| Gross profit | — | — | — | 0 | 50 | 44 | 128 | 161 | 207 | 250 |
| Research and development | 14 | 34 | 41 | 53 | 50 | 51 | 45 | 50 | 21 | 32 |
| Operating income | −25 | −47 | −55 | −91 | −104 | −181 | −112 | −92 | −5 | 105 |
| Net income | −23 | −71 | −53 | −88 | −103 | −181 | −108 | −78 | 6 | 287 |
| Diluted EPS (US$) | −0.66 | −0.92 | −0.63 | −0.95 | −0.87 | −1.40 | −0.76 | −0.54 | 0.04 | 2.07 |
| Diluted shares (millions) | 35 | 77 | 85 | 93 | 118 | 129 | 142 | 143 | 146 | 139 |
| Cash flow | ||||||||||
| Cash from operations | −19 | −41 | −52 | −64 | −70 | −158 | −80 | −34 | 44 | 136 |
| Capital expenditure | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 1 | 0 | 0 |
| Free cash flow | −19 | −41 | −52 | −64 | −76 | −158 | −80 | −34 | 44 | 135 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 | 98 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 4 | 7 | 7 | 18 | 31 | 32 | 45 | 32 | 15 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 40 | 174 | 126 | 306 | 272 | 232 | 94 | 49 | 83 | 80 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 57 | 190 | 146 | 324 | 464 | 543 | 471 | 548 | 551 | 752 |
| Total liabilities | 21 | 24 | 33 | 26 | 56 | 64 | 65 | 170 | 173 | 170 |
| Shareholders' equity | 36 | 178 | 136 | 299 | 408 | 479 | 405 | 378 | 378 | 581 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | 100.0% | 100.0% | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating margin | −14,466.5% | −11,212.4% | −11,930.9% | −28,598.4% | −208.1% | −396.3% | −83.2% | −52.2% | −2.0% | 37.1% |
| Net margin | −13,465.3% | −16,935.9% | −11,464.1% | −27,794.0% | −204.9% | −396.8% | −80.7% | −44.5% | 2.5% | 101.5% |
| Free cash flow margin | −10,825.4% | −9,855.0% | −11,153.6% | −20,022.6% | −150.7% | −346.4% | −59.5% | −19.5% | 18.8% | 47.8% |
| Rule of 40 (growth + FCF margin) | — | −9,713.4% | −11,142.8% | −20,054.0% | 15,509.7% | −355.4% | 134.3% | 11.5% | 52.7% | 68.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −66.2% | −33.9% | −40.7% | −29.1% | −40.8% | −24.5% | −19.9% | 1.5% | 59.9% |
| Return on assets | — | −57.4% | −31.6% | −37.6% | −26.1% | −35.9% | −21.3% | −15.3% | 1.1% | 44.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |